HGF/c-Met在肝细胞癌中作用的研究进展  

Advances in the study of HGF/c-Met in hepatocellular carcinoma

作　　者：徐倩文 孟迪 孙秀威[1] XU Qianwen;MENG Di;SUN Xiuwei(Medical Department,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院内科,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2022年第8期1504-1507,共4页Journal of Modern Oncology

摘　　要：肝细胞癌是世界上最具破坏力的癌症之一,其主要治疗方式为手术治疗,但大部分患者确诊时已失去手术机会,仅部分患者可行手术治疗,且术后的转移率及复发率较高,近期相关研究发现,肝细胞生长因子(HGF)/间充质-上皮转换受体(c-Met)轴的异常激活与HCC的转移潜力及预后不良相关,为肝细胞癌的靶向治疗提供新方向。目前针对HGF/c-Met信号传导途径的有效治疗药物仍处于研究重点,现就HGF/c-Met通路在肝细胞癌中的研究进展进行综述。Hepatocellular carcinoma(HCC)is one of the most destructive cancer in the world,and its main treatment is surgery,but the majority of patients diagnosed with lost surgery opportunity,only partially feasible surgical treatment for patients,and postoperative metastatic rate and recurrence rate are high.The recent related research found that hepatocyte growth factor(HGF)ectomesenchymal-epithelial conversion/receptor(c-Met)axis of the abnormal activation associated with the metastatic potential and prognosis of HCC,and provide a new direction for the targeted treatment of hepatocellular carcinoma.At present,effective therapeutic drugs for HGF/c-Met signaling pathway are still in the research focus.This article reviews the research progress of HGF/c-Met pathway in hepatocellular carcinoma.

关 键 词：肝细胞癌 HGF/C-MET c-Met抑制剂 

分 类 号：R735.7[医药卫生—肿瘤]